Event in Progress:
Discover the latest content that has just been published on Research Tree
9th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Helix Exploration (HEX.L) a helium exploration company with operations in Montana, USA announces admission of its Ordinary Shares to trading on the AIM market of the London Stock Exchange. An Oversubscribed placing with book of demand over £22m to raise gross proceeds of
Companies: SUN ORCP HVO VLG LGRS DXRX CCS AEE
Hybridan
Today's news and views, plus announcements from: VOD, SEIT, CMCX, DXRX, CUSN, TRR, & WINE.
Companies: TRR SEIT DXRX CUSN
Capital Access Group
Today's news and views, plus announcements from: DGE, PETS, HILS, DEC, STEM, RWI, & DXRX.
Companies: Diaceutics Plc
Diaceutics has released a trading statement for the year to December 2023 guiding to revenue growth of 22% YoY to £23.7m, up 19% on a constant currency basis. The order book jumped 57% to £26.6m, of which c£12.3m is expected to be realised in FY24, and which currently stands at £30.8m. The proportion of recurring revenue continues to increase and is now over 50% (FY22 35%). Cash at YE23 stood at £16.7m, indicating a near halving of the rate of cash burn in 2H23 compared to 1H23. We adjust our FY
26th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment ob
Companies: TMG SNT QTX PEG PEG OBD JNEO EQT DXRX COG COG
Diaceutics reported interim results reflecting the trading update for revenue, growth and composition. The gross profit for the half was £8.7m, up 38% YoY generating a gross margin of 88% (1H22 84%), despite the pressure on pharma industry spend in 1H23 which has now reversed. We leave our forecasts unchanged but with increased confidence that they will be met or exceeded. The business continues to perform in line with the growth path forged by Peter Keeling, but after 18 years, Mr Keeling is to
Today's news and views, plus announcements from: RIO, BNZL, IGG, BYG, & DXRX.
Companies: Rio Tinto plc (RIO:LON)Diaceutics Plc (DXRX:LON)
Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in
Companies: ALU WYN AFRN TSTL DXSP AEO HVO DXRX
Diaceutics has released its trading statement for the half year to the end of June, ahead of the interim results to be published on 26 September. The company reported revenue growth of 32% YoY and growth in the order book of 43%. Cash and net cash ended the period at £17.9m and the company remains fully funded to execute the growth strategy it announced in January. Diaceutics is becoming the primary commercialisation partner for pharma companies launching precision medicines with 21 of the top 3
5th June 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv
Companies: IRON SRES TSTL GTC ORCP DXRX CEG VRCI
Diaceutics has announced a new US$10.1m multi-year enterprise engagement with a top 10 global pharma company covering a wide range of Diaceutics' subscription data services to be delivered via the company's DXRX platform. The three-year contract includes additional options which could result in a significant increase in the scope and value of the contract.
17 April 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv
Companies: IGP RNO CNSL DXRX TEK SYS CER SUP
Today's news and views, plus announcements from: GSK WG., ASHM, DXRX, BOOM, AVCT, TEK, UOG, & EBQ.
Companies: DXRX UOG AVCT
As flagged with the trading statement, Diaceutics reported a 40% YoY increase in revenue to £19.5m generating EBITDA of £3.6m, up 53% YoY with diluted EPS of 0.84p, up 27% YoY. More important in our view, was the structural change in revenue generation to a recurring revenue model with platform-based subscription contracts accounting for 35% of revenue up from 3% in 2021, driving the development of a meaningful forward order book of £16.9m (FY21 £1.7m) for the first time. Cash and net cash ended
Research Tree provides access to ongoing research coverage, media content and regulatory news on Diaceutics Plc. We currently have 167 research reports from 6 professional analysts.
Share: